Meeting
2023 ASCO Annual Meeting
Effect of disease status prior to T-cell depleted allogeneic stem cell transplantation on relapse-free and overall survival in patients with adverse-risk acute myeloid leukemia (AML).
Authors
Alexandra Ewa Rojek
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL
Alexandra Ewa Rojek , Mylove Mortel , Andrew S. Artz , Richard A. Larson , Hongtao Liu , Mariam Nawas , Olatoyosi Odenike , Wendy Stock , Michael Russell Bishop , Satyajit Kosuri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Allogenic Stem Cell Transplantation
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7049)
DOI
10.1200/JCO.2023.41.16_suppl.7049
Abstract #
7049
Poster Bd #
179
Abstract Disclosures
Similar Posters
First Author: Haley Newman
Poster
2016 ASCO Annual Meeting
Evaluation of cytomegalovirus (CMV) reactivation, relapse, and survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) using two T cell depletion strategies.
First Author: Talal Hilal
Poster
2016 ASCO Annual Meeting
Long-term outcomes of non-myeloablative allogeneic stem cell transplantation (alloSCT) in patients with relapsed mantle cell lymphoma (MCL).
First Author: Issa F. Khouri
Poster
2024 ASCO Annual Meeting
Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
First Author: Olalekan O. Oluwole